[ad_1]
Synopsis
A study in the US has flagged serious adverse events linked to long-term use of gabapentin and pregabalin, which are widely prescribed to treat diabetic neuropathy. Viatris, the market leader, has disputed the study and downplayed the risks. While doctors have called for a closer study and a vigilance programme, what should be the course of action meanwhile?
Canadian physician William Osler is said to have once remarked that medicine is a science of uncertainty and an art of probability. The quote by Osler, known as the father of modern medicine, has of late been recalled during discussions among doctors in light of a study associated with two widely prescribed drugs used to treat diabetic neuropathy. The condition affects diabetes patients who have nerve-tissue damage that manifests in severe pain,
BY
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Uh-oh! This is an exclusive story available for selected readers only.
Worry not. You’re just a step away.
Congratulations! This story is unlocked for you.
We’ve rewarded you with ET Prime access for 30 days!
Clean ad-free reading experience on The Economic Times
Unlimited access to exclusive stories & insights across 20+ sectors
In-depth reports on 4000+ Stocks, updated daily
Complete access to ET Print Edition, the digital newspaper
Activate your Access
No card details required
Why ?
Exclusive Economic Times Stories, Editorials & Expert opinion across 20+ sectors
Stock analysis. Market Research. Industry Trends on 4000+ Stocks
Clean experience with
Minimal Ads
Comment & Engage with ET Prime community 
Exclusive invites to Virtual Events with Industry Leaders 
A trusted team of Journalists & Analysts who can best filter signal from noise
[ad_2]
Source link
